Journal of Endocrinological Investigation

, Volume 39, Issue 10, pp 1087–1094 | Cite as

Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients

  • M. G. CastagnaEmail author
  • S. Cantara
  • F. Pacini


Radioactive iodine therapy is administered to patients with differentiated thyroid cancer (DTC) for eradication of thyroid remnant after total thyroidectomy or, in patients with metastatic disease, for curative or palliative treatment. In past years, thyroid remnant ablation was indicated in almost every patient with a diagnosis of DTC. Nowadays, careful revision of patients’ outcome has introduced the concept of risk-based selection of patients candidate to thyroid remnant ablation. The present review aims to underline the indications for thyroid remnant ablation and to address methodologies to be employed.


Radioiodine Thyroid ablation Thyroid cancer Thyroglobulin rhTSH 



This work was supported in part by Grants from: Ministero Italiano dell’Università e Ricerca (MIUR) (Grant Number 2012Z3F7HE).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by the author.

Informed consent

Formal consent is not required.


  1. 1.
    Aschebrook-Kilfoy B, Ward MH, Sabra MM et al (2011) Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 21:125–134CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Leenhardt L, Bernier MO, Boin-Pineau MH et al (2004) Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 150:133–139CrossRefPubMedGoogle Scholar
  3. 3.
    Haugen BR, Alexander EK, Bible KC et al (2016) American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1–133CrossRefPubMedGoogle Scholar
  4. 4.
    Pacini F (2015) Observation for newly diagnosed micro-papillary thyroid cancer: is now the time? J Endocrinol Invest 38:101–102CrossRefPubMedGoogle Scholar
  5. 5.
    Pacini F, Schlumberger M, Harmer C et al (2005) Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 153:651–659CrossRefPubMedGoogle Scholar
  6. 6.
    Pacini F, Brianzoni E, Durante C et al (2016) Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. J Endocrinol Invest 39:341–347CrossRefPubMedGoogle Scholar
  7. 7.
    Jonklaas J, Sarlis NJ, Litofsky D et al (2006) Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229–1242CrossRefPubMedGoogle Scholar
  8. 8.
    Sacks W, Fung CH, Chang JT et al (2010) The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 20:1235–1245CrossRefPubMedGoogle Scholar
  9. 9.
    Kazaure HS, Roman SA, Sosa JA (2012) Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 19:1874–1880CrossRefPubMedGoogle Scholar
  10. 10.
    Regalbuto C, Malandrino P, Frasca F et al (2013) The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes. J Endocrinol Invest 36:249–254PubMedGoogle Scholar
  11. 11.
    Radowsky JS, Howard RS, Burch HB et al (2014) Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome. Thyroid 24:241–244CrossRefPubMedGoogle Scholar
  12. 12.
    Nixon IJ, Ganly I, Patel S et al (2011) The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery 150:1242–1249CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ahn D, Sohn JH, Jeon JH et al (2014) Clinical impact of microscopic extrathyroidal extension in patients with papillary thyroid microcarcinoma treated with hemithyroidectomy. J Endocrinol Invest 37:167–173CrossRefPubMedGoogle Scholar
  14. 14.
    Ruel E, Thomas S, Dinan M et al (2015) Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab 100:1529–1536CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Adam MA, Pura J, Goffredo P et al (2015) Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol 33:2370–2375CrossRefPubMedGoogle Scholar
  16. 16.
    Randolph GW, Duh QY, Heller KS et al (2012) The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22:1144–1152CrossRefPubMedGoogle Scholar
  17. 17.
    Xing M, Alzahrani AS, Carson KA et al (2013) Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493–1501CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tufano RP, Teixeira GV, Bishop J et al (2012) BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine 91:274–286CrossRefPubMedGoogle Scholar
  19. 19.
    Elisei R, Viola D, Torregrossa L et al (2012) The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97:4390–4398CrossRefPubMedGoogle Scholar
  20. 20.
    Kim TY, Kim WB, Rhee YS et al (2006) The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 65:364–368CrossRefGoogle Scholar
  21. 21.
    Li F, Chen G, Sheng C et al (2015) BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocr Relat Cancer 22:159–168CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Niemeier LA, Kuffner AH, Song C et al (2012) A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 118:2069–2077CrossRefPubMedGoogle Scholar
  23. 23.
    Piccardo A, Arecco F, Puntoni M et al (2013) Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin Nucl Med 38:18–24CrossRefPubMedGoogle Scholar
  24. 24.
    Lee JI, Chung YJ, Cho BY et al (2013) Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma. Surgery 153:828–835CrossRefPubMedGoogle Scholar
  25. 25.
    Rosario PW, Mineiro Filho AF, Prates BS et al (2012) Postoperative stimulated thyroglobulin of less than 1 ng/mL as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid 22:1140–1143CrossRefPubMedGoogle Scholar
  26. 26.
    Ibrahimpasic T, Nixon IJ, Palmer FL et al (2012) Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer—is there a need for radioactive iodine therapy? Surgery 152:1096–1105CrossRefPubMedGoogle Scholar
  27. 27.
    Webb RC, Howard RS, Stojadinovic A et al (2012) The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab 97:2754–2763CrossRefPubMedGoogle Scholar
  28. 28.
    Polachek A, Hirsch D, Tzvetov G et al (2011) Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer. J Endocrinol Invest 34:855–860PubMedGoogle Scholar
  29. 29.
    Piccardo A, Arecco F, Morbelli S et al (2010) Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer. J Endocrinol Invest 33:83–87CrossRefPubMedGoogle Scholar
  30. 30.
    Lima N, Cavaliere H, Tomimori E et al (2002) Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer. J Endocrinol Invest 25:110–115CrossRefPubMedGoogle Scholar
  31. 31.
    Heemstra KA, Liu YY, Stokkel M et al (2007) Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol 66:58–64Google Scholar
  32. 32.
    Robenshtok E, Grewal RK, Fish S et al (2013) A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients. Thyroid 23:436–442CrossRefPubMedGoogle Scholar
  33. 33.
    Rosario PW, Furtado MS, Mineiro Filho AF et al (2012) Value of repeat stimulated thyroglobulin testing in patients with differentiated thyroid carcinoma considered to be free of disease in the first year after ablation. Thyroid 22:482–486CrossRefPubMedGoogle Scholar
  34. 34.
    Nascimento C, Borget I, Al Ghuzlan A et al (2011) Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer 18:29–40Google Scholar
  35. 35.
    Schvartz C, Bonnetain F, Dabakuyo S et al (2012) Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 97:1526–1535CrossRefPubMedGoogle Scholar
  36. 36.
    Jonklaas J, Cooper DS, Ain KB et al (2010) Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 20:1423–1424CrossRefPubMedGoogle Scholar
  37. 37.
    Momesso DP, Vaisman F, Caminha LS et al (2014) Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer. J Endocrinol Invest 37:57–64CrossRefPubMedGoogle Scholar
  38. 38.
    Rosário PW, Borges MA, Valadão MM et al (2007) Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm? Thyroid 17:1225–1228CrossRefPubMedGoogle Scholar
  39. 39.
    Nixon IJ, Ganly I, Patel SG et al (2013) The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 23:683–694CrossRefPubMedGoogle Scholar
  40. 40.
    Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2004) A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135:139–148CrossRefPubMedGoogle Scholar
  41. 41.
    Hay ID, Hutchinson ME, Gonzalez-Losada T et al (2008) Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 144:980–987CrossRefPubMedGoogle Scholar
  42. 42.
    Baudin E, Travagli JP, Ropers J et al (1998) Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 83:553–559CrossRefPubMedGoogle Scholar
  43. 43.
    Melo M, Costa G, Ribeiro C et al (2013) Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later. J Clin Endocrinol Metab 98:4364–4372CrossRefPubMedGoogle Scholar
  44. 44.
    Edmonds CJ, Hayes S, Kermode JC et al (1977) Measurement of serum TSH and thyroid hormones in the management and treatment of thyroid carcinoma with radioiodine. Br J Radiol 50:799–807CrossRefPubMedGoogle Scholar
  45. 45.
    Marturano I, Russo M, Spadaro A et al (2015) Comparison of conventional l-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing. J Endocrinol Invest 38:1017–1022CrossRefPubMedGoogle Scholar
  46. 46.
    Pacini F, Ladenson PW, Schlumberger M et al (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926–932CrossRefPubMedGoogle Scholar
  47. 47.
    Chianelli M, Todino V, Graziano F et al (2006) Low dose (2.0 GBq; 54 mCi) radioiodine postsurgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low risk patients. Eur J Endocrinol 160:431–436CrossRefGoogle Scholar
  48. 48.
    Schlumberger M, Catargi B, Borget I et al (2012) Strategies of radioiodine ablation in patients with low-risk thyroid cancer. NEJM 366:1663–1673CrossRefPubMedGoogle Scholar
  49. 49.
    Mallick U, Harmer C, Yap B et al (2012) Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. NEJM 366:1674–1685CrossRefPubMedGoogle Scholar
  50. 50.
    Tuttle RM, Brokhin M, Omry G et al (2008) Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49:764–770CrossRefPubMedGoogle Scholar
  51. 51.
    Molinaro E, Giani C, Agate L et al (2013) Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity 131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J Clin Endocrinol Metab 98:2693–2700CrossRefPubMedGoogle Scholar
  52. 52.
    Castagna MG, Cevenini G, Theodoropoulou A et al (2013) Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol 169:23–29CrossRefPubMedGoogle Scholar
  53. 53.
    Taieb D, Sebag F, Cherenko M et al (2009) Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol 71:115–123CrossRefGoogle Scholar
  54. 54.
    Hanscheid H, Lassmann M, Luster M et al (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648–654PubMedGoogle Scholar
  55. 55.
    Frigo A, Dardano A, Danese E et al (2009) Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. J Clin Endocrinol Metab 94:3472–3476CrossRefPubMedGoogle Scholar
  56. 56.
    Borget I, Remy H, Chevalier J et al (2008) Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 35:1457–1463CrossRefPubMedGoogle Scholar
  57. 57.
    Tu J, Wang S, Huo Z et al (2014) Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis. Radiother Oncol 110:25–30CrossRefPubMedGoogle Scholar
  58. 58.
    Bal C, Padhy AK, Jana S et al (1996) Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 77:2574–2580CrossRefPubMedGoogle Scholar
  59. 59.
    Tresoldi AS, Sburlati LF, Rodari M et al (2014) Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer. J Endocrinol Invest 37:709–714CrossRefPubMedGoogle Scholar
  60. 60.
    Fang Y, Ding Y, Guo Q et al (2013) Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network meta-analyses. J Endocrinol Invest 36:896–902PubMedGoogle Scholar
  61. 61.
    Pilli T, Brianzoni E, Capoccetti F et al (2007) A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542–3546CrossRefPubMedGoogle Scholar
  62. 62.
    Maenpaa HO, Heikkonen J, Vaalavirta L et al (2008) Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS ONE 2(3):e1885CrossRefGoogle Scholar
  63. 63.
    Verburg FA, Mader U, Reiners C et al (2014) Long term survival in DTC is worse after low-activity initial post-surgical I-131 therapy in both high and low risk patients. J Clin Endocrinol Metab 99:4487–4496CrossRefPubMedGoogle Scholar
  64. 64.
    Franzius C, Dietlein M, Biermann M et al (2007) Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. Nuklearmedizin 46:224–231PubMedGoogle Scholar
  65. 65.
    Jarzab B, Handkiewicz-Junak D, Wloch J (2005) Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer 12:773–803CrossRefPubMedGoogle Scholar
  66. 66.
    Lassmann M, Hanscheid H, Chiesa C et al (2008) EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35:1405–1412CrossRefPubMedGoogle Scholar
  67. 67.
    Van Nostrand D, Moreau S, Bandaru VV et al (2010) (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid 20:879–883CrossRefPubMedGoogle Scholar
  68. 68.
    Muratet JP, Giraud P, Daver A et al (1997) Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. J Nucl Med 38:1362–1368PubMedGoogle Scholar
  69. 69.
    Leger AF, Pellan M, Dagousset F et al (2005) A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments. Br J Radiol 78:428–432CrossRefPubMedGoogle Scholar
  70. 70.
    Hilditch TE, Dempsey MF, Bolster AA et al (2002) Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging 29:783–788CrossRefPubMedGoogle Scholar
  71. 71.
    Silberstein EB (2007) Comparison of outcomes after (123)I versus (131)I pre ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med 48:1043–1046CrossRefPubMedGoogle Scholar
  72. 72.
    Avram AM, Esfandiari NH, Wong KK (2015) Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning. J Clin Endocrinol Metab 100:1895–1902CrossRefPubMedGoogle Scholar
  73. 73.
    Pluijmen MJ, Eustatia-Rutten C, Goslings BM et al (2003) Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol 58:428–435CrossRefGoogle Scholar
  74. 74.
    Sawka AM, Ibrahim-Zada I, Galacgac P et al (2010) Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. Thyroid 20:1129–1138CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Tala Jury HP, Castagna MG, Fioravanti C et al (2010) Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab 95:230–237CrossRefPubMedGoogle Scholar
  76. 76.
    Fatourechi V, Hay ID, Mullan BP et al (2000) Are post-therapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 10:573–577CrossRefPubMedGoogle Scholar
  77. 77.
    Souza Rosario PW, Barroso AL, Rezende LL et al (2004) Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med 29:795–798CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2016

Authors and Affiliations

  1. 1.Department of Medical, Surgical and Neurological SciencesUniversity of SienaSienaItaly

Personalised recommendations